Core Insights - Zimmer Biomet Holdings, Inc. is a global leader in musculoskeletal healthcare, focusing on orthopedic reconstructive products and competing with major players like Stryker Corporation and Johnson & Johnson [1] Financial Performance - In the third quarter, Zimmer Biomet reported an adjusted EPS of $1.90, a 9.2% increase year-over-year, exceeding the Zacks Consensus Estimate by 1.06% [3] - The company's revenue grew by 9.7% to $2 billion, but this fell short of expectations, resulting in an 8.1% decline in pre-market trading [3] Stock Performance - The current stock price for ZBH is $87.58, reflecting a decrease of 15.12% with a change of -$15.6, and has fluctuated between a low of $85.84 and a high of $93.94 today [4] - Over the past year, the stock reached a high of $114.72 and a low of $85.84, with a market capitalization of approximately $17.35 billion [4] Analyst Outlook - On November 5, 2025, Rick Wise from Stifel Nicolaus set a price target of $110 for ZBH, indicating a potential upside of approximately 25.13% from the current trading price of $87.91 [2] - Despite recent challenges, the company reaffirmed its EPS guidance while narrowing its revenue growth outlook for 2025 [5] - The trading volume for the day is 8,564,601 shares on the NYSE, indicating active investor interest [5]

Core Insights - Zimmer Biomet, a manufacturer of knee and hip replacements, reported quarterly sales that fell short of estimates and has revised down the upper limit of its full-year organic revenue growth outlook [1] Company Summary - The company missed quarterly sales estimates, indicating potential challenges in meeting market expectations [1] - Zimmer Biomet has lowered the top end of its outlook for full-year organic revenue growth, suggesting a more conservative approach to future revenue projections [1]